Safety Study of Olopatadine Nasal Spray
Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Perennial Allergic Rhinitis
Intervention: Olopatadine 0.6% nasal spray (Drug); Placebo Nasal Spray (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Alcon Research Official(s) and/or principal investigator(s):
Margaret Drake, Study Director, Affiliation: Alcon Research
Summary
The purpose of this study is to determine whether olopatadine nasal spray is safe and
effective when used for up to one year by patients with perennial allergic rhinitis.
Clinical Details
Official title: Safety Study of Olopatadine Nasal Spray
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Mean Response at Day 30 to the Patient-rated Relief Assessment Questionnaire
Secondary outcome: Average Number of Days of Rescue Medication Taken
Eligibility
Minimum age: 12 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with confirmed diagnosis of perennial allergic rhinitis who are 12 years and
older
Exclusion Criteria:
- Age 11 years and younger
Locations and Contacts
Waco, Waco, Texas 76712, United States
Additional Information
Starting date: December 2006
Last updated: February 23, 2010
|
